<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295202</url>
  </required_header>
  <id_info>
    <org_study_id>SDC 4075/14/055</org_study_id>
    <nct_id>NCT02295202</nct_id>
  </id_info>
  <brief_title>Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome</brief_title>
  <acronym>TREATOSA-MS</acronym>
  <official_title>Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome: A Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fleury</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive Sleep Apnea (OSA) is a common condition that may induce hemodynamic and metabolic
      dysregulation. However, it is not clear if OSA is a mere epiphenomenon or contributes to
      increase the morbidity associated with metabolic syndrome. This study was designed to
      evaluate the impact of OSA treatment with CPAP in consecutive patients with metabolic
      syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reversibility of Metabolic Syndrome criteria</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abdominal fat</measure>
    <time_frame>6 months</time_frame>
    <description>Abdominal CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic steatosis</measure>
    <time_frame>6 months</time_frame>
    <description>Abdominal CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carotid intima-media thickness</measure>
    <time_frame>6 months</time_frame>
    <description>Carotid ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endothelial function</measure>
    <time_frame>6 months</time_frame>
    <description>Braquial artery ultrasound (flow mediated dilation, %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coronary atherosclerosis</measure>
    <time_frame>6 months</time_frame>
    <description>Coronary CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>6 months</time_frame>
    <description>C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomics</measure>
    <time_frame>6 months</time_frame>
    <description>Metabolomic analysis (intended to be a sub-study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MicroRNAs</measure>
    <time_frame>6 months</time_frame>
    <description>MicroRNAs analysis (intended to be a sub-study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epicardic fat</measure>
    <time_frame>6 months</time_frame>
    <description>Epicardic fat quantification by CT (intended to be a sub-study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart remodeling</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluated by Tranthoracic echocardiography (intended to be a sub-study)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Sleep Apnea</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>CPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPAP: Continuous Positive Airway Pressure - Device used for treating OSA during sleep.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nasal Strips</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP (REMstar System One Plus - Philips Medical Systems)</intervention_name>
    <description>Standard device for treating obstructive sleep apnea.</description>
    <arm_group_label>CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasal strips</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metabolic Syndrome (ATP III)

          -  Moderate to severe OSA

        Exclusion Criteria:

          -  Smokers

          -  Patients under chronic use of medications

          -  Neurological diseases

          -  Coronary artery disease

          -  Acute heart failure

          -  Chronic renal failure (GFR &lt; 30 ml/min)

          -  Chronic obstructive pulmonary disease

          -  Mild OSA and patients with BMI over 40 kg/m2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciano F Drager, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Institute (InCor), University of Sao Paulo Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Luciano Drager</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 12, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Luciano F Drager, MD, PhD</investigator_full_name>
    <investigator_title>Luciano F. Drager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

